FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208491640> ?p ?o ?g. }

• W3208491640 endingPage "2904" @default.
• W3208491640 startingPage "2904" @default.
• W3208491640 abstract "Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited therapeutic options. Metastasis is the major cause of TNBC mortality. Angiogenesis facilitates TNBC metastases. Many TNBCs also form vascular channels lined by tumor cells rather than endothelial cells, known as 'vasculogenic mimicry' (VM). VM has been linked to metastatic TNBC behavior and resistance to anti-angiogenic agents. Epidermal growth factor receptor (EGFR) is frequently expressed on TNBC, but anti-EGFR antibodies have limited efficacy. We synthesized an anti-EGFR antibody-endostatin fusion protein, αEGFR IgG1-huEndo-P125A (αEGFR-E-P125A), designed to deliver a mutant endostatin, huEndo-P125A (E-P125A), to EGFR expressing tumors, and tested its effects on angiogenesis, TNBC VM, and motility in vitro, and on the growth and metastasis of two independent human TNBC xenograft models in vivo. αEGFR-E-P125A completely inhibited the ability of human umbilical vein endothelial cells to form capillary-like structures (CLS) and of TNBC cells to engage in VM and form tubes in vitro. αEGFR-E-P125A treatment reduced endothelial and TNBC motility in vitro more effectively than E-P125A or cetuximab, delivered alone or in combination. Treatment of TNBC with αEGFR-E-P125A was associated with a reduction in cytoplasmic and nuclear β-catenin and reduced phosphorylation of vimentin. αEGFR-E-P125A treatment of TNBC xenografts in vivo inhibited angiogenesis and VM, reduced primary tumor growth and lung metastasis of orthotopically implanted MDA-MB-468 TNBC cells, and markedly decreased lung metastases following intravenous injection of MDA-MB-231-4175 lung-tropic TNBC cells. Combined inhibition of angiogenesis, VM, and TNBC motility mediated by αEGFR-E-P125A is a promising strategy for the prevention of TNBC metastases." @default.
• W3208491640 created "2021-11-08" @default.
• W3208491640 creator A5008382180 @default.
• W3208491640 creator A5020595062 @default.
• W3208491640 creator A5027629181 @default.
• W3208491640 creator A5034810100 @default.
• W3208491640 creator A5038805688 @default.
• W3208491640 creator A5042353099 @default.
• W3208491640 creator A5053578977 @default.
• W3208491640 creator A5060976304 @default.
• W3208491640 creator A5066974332 @default.
• W3208491640 creator A5071773009 @default.
• W3208491640 creator A5072552636 @default.
• W3208491640 creator A5085548742 @default.
• W3208491640 creator A5089187377 @default.
• W3208491640 date "2021-10-27" @default.
• W3208491640 modified "2023-10-16" @default.
• W3208491640 title "Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases" @default.
• W3208491640 cites W1579297325 @default.
• W3208491640 cites W1978068596 @default.
• W3208491640 cites W1979486580 @default.
• W3208491640 cites W1987373390 @default.
• W3208491640 cites W1991120755 @default.
• W3208491640 cites W1993655973 @default.
• W3208491640 cites W1994250985 @default.
• W3208491640 cites W1998734250 @default.
• W3208491640 cites W2004781757 @default.
• W3208491640 cites W2006419043 @default.
• W3208491640 cites W2008129323 @default.
• W3208491640 cites W2008321434 @default.
• W3208491640 cites W2014331589 @default.
• W3208491640 cites W2018702739 @default.
• W3208491640 cites W2032012444 @default.
• W3208491640 cites W2033152464 @default.
• W3208491640 cites W2038819621 @default.
• W3208491640 cites W2054484461 @default.
• W3208491640 cites W2077282333 @default.
• W3208491640 cites W2082833890 @default.
• W3208491640 cites W2090587373 @default.
• W3208491640 cites W2096027508 @default.
• W3208491640 cites W2102061082 @default.
• W3208491640 cites W2104485396 @default.
• W3208491640 cites W2107178841 @default.
• W3208491640 cites W2108658668 @default.
• W3208491640 cites W2116361774 @default.
• W3208491640 cites W2120344622 @default.
• W3208491640 cites W2131798870 @default.
• W3208491640 cites W2135832539 @default.
• W3208491640 cites W2140754975 @default.
• W3208491640 cites W2142928449 @default.
• W3208491640 cites W2145896038 @default.
• W3208491640 cites W2150478512 @default.
• W3208491640 cites W2150515510 @default.
• W3208491640 cites W2153769134 @default.
• W3208491640 cites W2156384462 @default.
• W3208491640 cites W2157642143 @default.
• W3208491640 cites W2161708429 @default.
• W3208491640 cites W2262828252 @default.
• W3208491640 cites W2285547302 @default.
• W3208491640 cites W2313296912 @default.
• W3208491640 cites W2319938999 @default.
• W3208491640 cites W2334281591 @default.
• W3208491640 cites W2342435575 @default.
• W3208491640 cites W2342698425 @default.
• W3208491640 cites W2442993671 @default.
• W3208491640 cites W2589522830 @default.
• W3208491640 cites W2605994569 @default.
• W3208491640 cites W2619876526 @default.
• W3208491640 cites W2775823627 @default.
• W3208491640 cites W2793453271 @default.
• W3208491640 cites W2891101213 @default.
• W3208491640 cites W2897422388 @default.
• W3208491640 cites W2908691578 @default.
• W3208491640 cites W2966611204 @default.
• W3208491640 cites W3008989437 @default.
• W3208491640 cites W3043396041 @default.
• W3208491640 cites W3095726546 @default.
• W3208491640 cites W3119081011 @default.
• W3208491640 cites W4211089574 @default.
• W3208491640 cites W4247579471 @default.
• W3208491640 doi "https://doi.org/10.3390/cells10112904" @default.
• W3208491640 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8616280" @default.
• W3208491640 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34831127" @default.
• W3208491640 hasPublicationYear "2021" @default.
• W3208491640 type Work @default.
• W3208491640 sameAs 3208491640 @default.
• W3208491640 citedByCount "7" @default.
• W3208491640 countsByYear W32084916402022 @default.
• W3208491640 countsByYear W32084916402023 @default.
• W3208491640 crossrefType "journal-article" @default.
• W3208491640 hasAuthorship W3208491640A5008382180 @default.
• W3208491640 hasAuthorship W3208491640A5020595062 @default.
• W3208491640 hasAuthorship W3208491640A5027629181 @default.
• W3208491640 hasAuthorship W3208491640A5034810100 @default.
• W3208491640 hasAuthorship W3208491640A5038805688 @default.
• W3208491640 hasAuthorship W3208491640A5042353099 @default.
• W3208491640 hasAuthorship W3208491640A5053578977 @default.
• W3208491640 hasAuthorship W3208491640A5060976304 @default.

• next